Animal Care Experiences Significant Surge in Customer Adoption, Bolstering Confidence in Product Efficacy and Health Economic Metrics
Scandinavian ChemoTech’s Animal Care operation is excited to announce a significant increase in the adoption of its vetIQure™ TSE system. This trend underscores the system’s effectiveness and its critical value to everyday oncology practices. Some clinics are now performing more than five TSE treatments per day, potentially exceeding 200 treatments annually. This is a significant increase from our earlier estimate of approximately 100 treatments per year.
In recent quarters, the Company has observed a marked rise in repeat purchases, reflecting the growing trust and satisfaction among veterinary professionals regarding the efficacy of its products. This surge in customer usage highlights the pivotal role that the TSE system plays in managing and treating various types of cancer in both horses and small pets.
"Our team at Vetiqure is thrilled to see our products being increasingly utilised by veterinary professionals worldwide. The rise in repeat purchases affirms the confidence our customers have in the science and health economic benefits of our products, showcasing their effectiveness in real-world veterinary practice” – says Mohan Frick, CEO for Scandinavian ChemoTech and Vetiqure.
Supporting this uptick in product usage, Vetiqure AB has received several orders totalling close to €200,000 from leading veterinary groups in the United States and Europe over the past six months. The orders come from both existing and new customers and include both devices and treatment kits.
Vetiqure AB's cutting-edge solutions have seamlessly integrated into the daily routines of veterinary practitioners, offering reliable tools to address the complex challenges of oncology care in animals. The minimally invasive TSE System, grounded in advanced science and strong health economic metrics, empowers veterinarians to provide optimal care while ensuring cost-effectiveness for pet owners.
"We are proud to support veterinary professionals in their mission to improve the lives of animals affected by cancer. During my recent visits to the USA and Western Europe, I observed a significant increase in the adoption of our solutions. This growth not only reflects on the efficacy of our TSE therapy but also the trust and confidence placed in us as a company and the vetIQure™ TSE system by the veterinary community.", further added Mohan Frick.
As Vetiqure AB continues to experience growing demand for its oncology solutions, the company remains dedicated to advancing innovation in veterinary care and enhancing the quality of life for animals battling cancer.
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Certified Adviser: Redeye AB
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 10-06-2024 12:45 CET.
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.